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Introduction 
Lung cancer is the leading cause of cancer deaths
worldwide [1-3]. High mortality rate is first of all
due to the fact that most cases of lung cancer are
diagnosed in an advanced stage of development.
Better diagnostics of preinvasive conditions, which
are thought to be precancerous lesions, would cer-
tainly contribute to lowering the mortality rate.
However, it is a big challenge, considering that the
whole lung is a potential field of the cancerogenesis,
and that the neoplasia has many different potential
ways of development [5].
A long term exposure of the epithelium lining the
airways to different carcinogens, including most of all
cigarette smoke, causes a number of mutations of the
cells placed in different compartments.  These multi-
phase changes with a diversified morphology result in
the development of a fully invasive type of cancer
[6,7]. Thus, lung cancer may develop both in the pri-
mary bronchus, small bronchioli  and alveoli. 
The multistep carcinogenesis of the peripheral non-
small cell lung cancer of the lung still seems to be
unclear. Adenocarcinoma (AC) of the lung, which aris-
es mainly peripherally, is the common histological
type of lung cancer among patients around the world.
The frequency of the appearance of its precancerous
lesion - atypical adenomatous hyperplasia (AAH)  is
rather unknown [8-12]. Its occurrence is still unpro-
portionally infrequent compared to the number of
diagnosed AC. Thus, it is necessary to search for new
preneoplastic conditions that may complete the classi-
fication of the precancerous lesions leading to devel-
opment of peripheral lung cancer. In 2003 Ullman [4]
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nar cell dysplasia (BCCD) arising in small bronchioles
that may lead to adenocarcinoma. The thesis that ade-
nocarcinoma may arise from BCCD was supported
with LOH  studies showing loses of 6q23-ter, 12q23-
ter and 13q14-21 and gains 7q11-q21, 13q32-ter and
19q13.1 chromosomes both in BCCD and AC speci-
mens. In this paper we describe the morphological and
immunohistochemical analysis of P16INK4a, TP53, Rb
and Ki-67 proteins expression in this preneoplastic
lesion concerning small bronchioles that may lead
both to adenocarcinoma  as well as peripheral-squa-
mous carcinoma development. 
Materials and methods 
Material samples. We examined specimens taken form a popu-
lation of 193 patients (148 males, 45 females) surgically treated
for primary non-small cell lung cancer (lobectomy, bilobectomy
or pulmonectomy) in Department of Thoracic Surgery, Medical
University of Bialystok in 2003-2006. The age of the patients
ranged from 40 years to 77 years (mean 60.4 years). Four to six
tissue samples of tumour and 10 to 15 samples of not invaded
lung were taken from each specimen of all patients belonging to
the studied population. Samples were routinely formalin-fixed
and paraffin-embedded. For histological evaluation each 5 µm
section was H+E stained. Slides of each sample were investigat-
ed separately by two pathologists experienced in lung cancer
pathology using criteria for preneoplastic lesions according to
the WHO 1999 classification. All the cases were divided into
three groups corresponding to histological types of primary lung
cancer.
Immunohistochemistry.  Selected samples representing BCCD
(according to morphological criteria by Ullman et al.) obtained
from macroscopically normotype tissue were immunohistochemi-
caly examined. Paraffin blocks were cut for 5 µm thick slices,
placed on a microscopic slide and left in 56°C for 24 hours. Then
deparaffinization with subsequent xylens  was made. Deparaf-
finized specimens were then placed in following alcohol solutions
(absolute alcohol, 96%, 70%) in room temperature. Next, rinsed
with water specimens placed in citric buffer (pH=6.0; 55-60°C).
Series of 4 slides  were then microwaved (630W/20 min).
Immunohistochemical analysis was performed using monoclonal
mouse anti-human antibodies directed against P16INK4a (E64H,
1:25, DakoCytomation), TP53 (DO-7, 1:50, DakoCytomation), Rb
(1F8, 1:20, Novocastra Laboratories) and Ki67 (MIB-1, 1:75,
DakoCytomation) proteins. As a detection kit for P16INK4a, TP53
and Ki-67 biotin-strepatvidin-acidic phosphatase  (DakoCytoma-
tion) was used. For Rb detection we used Avidin/Biotin Blocking
System (Novocastra Laboratories). As a chromogen for all proteins
Substrate - chromogen solution (DAB) (DakoCytomation) was
used. Nuclei were then stained with Mayer hematoxylin. Positive
controls were made using tissue samples proposed by antibody
manufacturer which showed high expression of proteins. Negative
control were made with the same tissue without antibody. Expres-
sion of the proteins was recognized as positive when at least 10%
of the cells of observed lesion were stained. 
Statistical analysis. The association between immunohistochemi-
cal and histological parameters have been measured using Spear-
man rank correlation. Statistical analysis was performed with Sta-
tistica 6.0. Differences were recognized as significant when p was
<0.05.
Results 
The distribution of the preneoplastic lesions
In studied population of 193 patients we described as
much as 137 preneoplastic lesions in 101 patients. In
some of the cases we observed more than one lesion.
In most cases bronchiolization states  as an additional
change. The studied population was divided into three
groups corresponding with histological type of the pri-
mary tumour. In squamous carcinoma group (Group
SqC, n=54) leading lesion was squamous metaplasia
without or with dysplasia (63.5%). Carcinoma in situ
was present in 8.6% of the cases. Interestingly, BCCD
was observed in 17.6% while AAH and bronchioliza-
tion were present respectively in 2.7% and 8.1% of the
cases. The difference in number of the metaplasia in
this group comparying to others was statistically sig-
nificant (p<0,001).  In adenocarcinoma group (Group
AC, n=34) percentage of squamous metaplasia and
BCCD was aproximate (respectively 34.9% and
30.2%). In this group AAH was observed in 11.2% and
bronchiolization in 23.3% of the cases. The occurrence
of BCCD in this group in comparison to others was
statistically significant (p<0,05). Large cell lung can-
cer group (LCLC) was to small to provide any statisti-
cal analysis.
Morphology of BCCD
We observed that BCCD changes are mainly focal,
usually concern a short section of the bronchiolar
mucosa. That creates cardinal difficulties for far-reach-
ing studies of these lesions. The abnormalities relate to
the structure, number of the cells, as well as cytologi-
cal state of the epithelium. Columnar epithelium, typi-
cal for bronchioles with vertically oriented nucleus is
most often replaced by cells showing horizontal orien-
tation of the nucleus. Sometimes the cells take polyg-
onal or lengthened form. Often the epithelium arrange
into two, three or more layers. The cells showed cyto-
logical atypia. Mostly we observed enlarged nuclei,
showing horizontal orientation to the basal layer. Some
of the polinuclear cells were also described. Nuclei
usually is hiperchromatic, often with prominent nucle-
oli. Chromatin seems to be condensed and decom-
posed in the cell. Shapes of the nuclei are often irreg-
ular. Incidentally cells can differentiate into multilayer
squamous type epithelium. It occurs with creation of
the desomsomes. Very often foci of BCCD are found
in bronchioles, which shows focal disruption or disap-
pearance. Fig. 1 to 4 show all described characteristics.
Immunohistochemistry of BCCD
Thirty cases of BCCD found during histopathological
investigation were studied for immunoexpression of
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P16INK4a protein. Twenty one (70%) of the cases we
observed loss of expression of the P16INK4a protein.
Two cases (6.7%) represent abnormal expression of
the protein in cytoplasm. Mixed nuclear  - cytoplasmic
expression was observed in seven cases (23.3%). The
Spearman correlation rank test showed statistical sig-
nificance between lack of expression of these protein
and histological type of the tumor which was adeno-
carcinoma (p<0.001). 
TP53 protein. In eight cases of BCCD (26.7%) we
observed overexpression of TP53. Seven cases showed
nuclear expression, one case mixed nuclear - cytoplas-
mic expression. In remaining 22 cases we didn't
observe positive staining for TP53.
Rb protein. The presence of Rb protein in nuclei of the
cells was found in 14/29 cases of BCCD (48.3%). In
all remaining cases expression of this protein was not
observed. In one case there was no possibility to estab-
lish status of the Rb protein expression, because the
lesion was cut out while preparation of the slides.
Mitotic activity (Ki-67). Diversified expression of Ki-
67 (from 10 to 80% of stained cells) was observed in
10/28 cases of BCCD (35.7%). In all remaining cases
we didn't observed the expression of the protein or it
considered only single cells of the case. In two cases
there was no possibility to establish status of the mitot-
ic activity, because the lesion was cut out while prepa-
ration of the slides.
Figures 5-10 presents immunostaining of the
described proteins.
Discussion
High mortality because of the lung cancer comes out
mainly of the fact that majority of the cases are diag-
nosed in advanced stadium. An expanded diagnostics
of preinvasive conditions, which are referred to as pre-
cancerous lesions, would certainly contribute to lower-
ing the mortality rate. It is, however, a big challenge,
considering that the whole lung is a potential field of
cancerogenesis, and neoplasia has many different
potential ways of development [5]. 
Many studies show that the development of non-
small cell lung cancer, in particular squamous cell lung
cancer, is preceded by long-term period in which the
genetic - molecular changes in cells of the respiratory
epithelium take place. These multistep changes of dif-
ferent morphology provides to growth of fully inva-
sive cancer [7,13-15].
The multistep changes leading to development of
the invasive squamous cell lung cancer are well recog-
nized and described by many authors [6,16-19].
The transitions leading to the development of ade-
nocarcinoma, which states in Poland for 30% of all
diagnosed cases of non-small cell lung cancer is still
unclear. Many authors contribute that AAH leads to
non invasive form of bronchiolo-alveolar cancer as
well as to invasive adenocarcinoma. Unfortunately the
occurrence of this lesion in the population is not
known. In this study AAH states for 6.7% of all diag-
nosed preneoplastic lesions and although it was more
often present in AC-group (11.2%) than in SqCLC-
group (2.7%) we can tell that the occurrence of this
change was occasional. However studies of Nakahara
[9]  showed that AAH states for 23.2% of 508 exam-
ined cases, whereas Chapman and Kerr [8] indicated
only 12% cases of AAH in studied population of 582
patients. The frequence of the AAH in our studies is
quite low comparing to other literature data. This dis-
proportion is apparent and could result of two facts.
First of all, in countries of Western Europe and USA
the frequence of adenocarcinoma is higher. It has been
estimated that for the last 20 years in European coun-
tries the number of diagnosed adenocarcinoma and
lesions preceding its development among the young
men and women at all age raised up for about 10% [1].
In Poland the leading type of NSCLC is still squamous
cell lung cancer. Secondly in 2006 pathologists were
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Table 1. Expression of the proteins in SqCLC, AC and LCLC
groups of patients.
*cytoplasmic or nuclear cytoplasmic localization of the proteinpresented to more precise criteria of differentiating
AAH than in previous years [20]. 
Described results of others and our studies clearly
show the disproportion of the frequence of AAH and
development of adenocarcinoma in population. Thus,
it seems that the WHO classification of the precancer-
ous lesions leading to the peripheral tumors of the lung
is still incomplete. It is necessary to search for the
peripheral situated changes which could fill the theory
of invasive adenocarcinoma development. It is also
worthy to thing of the point the development of the
rare peripheral squamous cell lung cancer which states
for 5-6% of all surgically treated NSCLC [21,22]. In
our study in two cases we observed the differentiation
of the cells of bronchiolar epithelium into the squa-
mous multilayer epithelium, which reveal  with des-
omsomes formation. Thus, there occurs the hypothesis
that bronchioles might be a place of carcinogenesis for
both adenocarcinoma and squamous cell lung cancer
development.
Noted cases of the BCCD (most of all in group with
primary adenocarcinoma - 30.2%, and squamous cell
lung cacer - 17.6%) seems to support this thesis. The
additional argument that BCCD may be a real preneo-
plastic lesion are studies of the immunoexpression of
the cell cycle crucial proteins. 
Described BCCD cases are extremely difficult for
diagnosis because concern small bronchioles (0.3 - 1
mm). The changes are often very small, focal trans-
formation of the epithelial cells, which could be
revealed only after accurate diagnosis of all histolog-
ical material.
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Fig. 1. Bronchiolus with focal BCCD lesion - one layer of columnar or cuboidal epithelium was lined by multilayer epithelium formed
by elongated or polygonal cells with marks of atypia (M, primary cancer SqCLC, H+E, magnification × 400). Fig. 2. Fragment of the
bronchiolus wall with focal BCCD. Nuclei of the cells are concentrated, of different shapes (round, polygonal or elongated). Nuclear chro-
matin in granular aggregation (F, primary cancer AC, H+E, magnification × 400). Fig. 3. Fragment of the bronchiolar mucosa with chaot-
ically lined epithelium with morphological marks of atypia. Nuclei of different size with prominent nucleoli and unevenly arranged chro-
matin (M, primary cancer SqCLC, H+E, magnification × 400). Fig. 4. Fragment of bronchiolus. Preserved an island of the epithelium
with marks of squamous metaplasia with dysplasia (special and rare subtype of BCCD). Cells of the epithelium connected with each other
through desomsomes (M, primary cancer AC, H+E,  magnification × 100).It is thought that observed phenotype of the cells
suspected for neoplastic transformation is result of the
changes in genes and proteins that participates in reg-
ulation of the cell cycle and apoptosis as well as the
repairing of the DNA [23]. The changes in gene
expression and the structure of chromosomes  that lead
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Fig. 5. High cytoplasmic - nuclear expression of P16INK4a in bronchiolus with BCCD (M, primary cancer SqCLC, magnification × 40).
Fig. 6. Medium cytoplasmic - nuclear expression of P16INK4a in bronchiolus with BCCD (F, primary cancer AC, magnification × 200).
Fig. 7. Nuclear expression of TP53 in bronchiolus with BCCD (M, primary cancer SqCLC, magnification × 400). Fig. 8. Nuclear expres-
sion of TP53 in bronchiolus with BCCD (M, primary cancer LCLC, magnification × 200). Fig. 9. Low mitotic activity (Ki-67 protein) in
bronchiolus with BCCD (M, primary tumour SqCLC, magnification × 200). Fig. 10. High mitotic activity (Ki-67 protein) in bronchiolus
with BCCD (M, primary cancer SqCLC, magnification × 200).to cancer development are often observed in cases of
squamous metaplasia, dysplasia and CIS and AAH.
Changes occur sequentially so their number and fre-
quency raises with progress of atypia from metaplasia
- dysplasia - CIS and AAH - adenocarcinoma [13].
Loss of expression of the P16INK4a protein observed
in our study is common phenomenon in majority of
cancers and its preceding lesions [18,24-30]. In our
study 92.3% of the BCCD cases showing loss of
expression of P16INKa were from AC-group. In seven
of them it was probably linked with absence of the
active Rb protein in the cells. In cases from SqCLC-
group only one of five cases of loss of the protein
might be due to lack of Rb protein. Cytoplasmic
expression observed in this study is often refused by
other authors as non-specific reaction. Recent study of
the protein at sub-cellular level shows that this inter-
pretation could be wrong. It's been shown that cyto-
plasmic activity of this protein could be the result of its
inactivation or the mutation of the P16INK4a gene [31].
This thesis is supported by study showing cytoplasmic
localization of P16INK4a protein and highly malignant
phenotype of breast cancer [32].
Aberrances of TP53 protein are mainly observed
changes in invasive cancers. It play a leading role in
multistep cancer development [6,34]. Accumulation of
the TP53 is observed at an early stages of cancer
growth. The accumulation of this genetic and epige-
netic changes concerning TP53 states from 5% in
squamous metaplasia to even 60% in severe dysplasia
cases [35-38]. Brambilla [37] found no accumulation
of the TP53 in preneoplastic changes from non cancer
cases, so it may show that overexpression of TP53
results in invasive cancer development. Accumulation
of the protein in atypical adenomatous hyperplasia was
observed in 5 to 28% of the cases, where tumor tissue
showed overexpression of TP53 in 53 to 64% of the
cases [33], [39]. In our study accumulation of TP53
was observed in 26.7% of the cases. Most of the cases
were from the AC-group (38.5%). In SqCLC-group
the number of cases with overexpression of TP53 was
nearly twice lower (15.5%). It must be taken into
account that the immunohistochemical method is able
to define over-expression only in the case of protein
p53. Only the methods of molecular biology are able
to define mutation in exons, which do not lead to the
accumulation of protein in the cell and, therefore, are
not detectable by means of  the immunohistochemical
method [40].
The Rb gene mutations are often observed in series
of cancers [43-46]. Lack of expression of the Rb pro-
tein is the highest in small cell lung cancer (about
90%). In non-small cell lung cancers the frequency of
loss of expression is much lower (about 30%)
[34,47,48]. In precancerous lesions of the lung lack of
expression of the Rb protein is low and concerns up to
18% of the cases [25,49,50]. In our study the Rb loss
was quite high in BCCD cases from SqCLC-, AC-  and
LCLC-groups (46.1%, 53.8% and 50% respectively).
This high percentage could be accidental event that
results from low amount of examined cases. Although,
we could suggest the new way of transformation from
BCCD to small cell lung cancer development, which
not exclude according to new articles concerning
development from single stem cells mediating in
inflammation [41,42]. 
Other important marker differentiating stages of
development of the preneoplastic lesion is prolifera-
tive index (Ki-67). Raise of the mitotic activity that
correlates with growing level of dysplasia and atypia is
well known phenomenon described in epithelium of
many organs [51-53]. Meert [54] showed that the
expression of Ki-67 depends on level of development
of the preneoplastic lesion and grows significantly
from low dysplasia to CIS. Comparison of the topog-
raphy and intensity of the staining shows significant
difference between low dysplasia - moderate dysplasia
(47-67% of stained cells) and severe dysplasia -CIS
levels (91-100% of stained cells). Similarly mitotic
activity raises up with increasing level of atypia in
AAH to bronchiolo-alveolar cancer and invasive ade-
nocarcinoma [49]. 
In our study increased mitotic activity was
observed in 10 cases of BCCD (35.7%). Five cases
(38.5%) from SqCLC-group showed different levels of
mitotic activity from 10 to 80% of stained cells. The
raised proliferative index was nearly similar in cases
from AC-group (30.8%). Seven cases represents low
staining for Ki-67 (below 10% of the cells).
Conducted experiments did not show any dependence
between expression status of each protein and presence
of BCCD. Considering the fact that neoplastic trans-
formation is a multistep process the result is not sur-
prising. Concluding the shown above results we may
suppose that BCCD may be preneoplastic lesion lead-
ing to adenocarcinoma as well as to peripheral squa-
mous cell lung cancer. The hypothesis should be sup-
ported with further evidence, especially with results of
genetic - molecular studies.  
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